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Identity 
Other names: AIS, B(p51A), B(p51B), EEC3, KET, 
LMS, NBP, OFC8, RHS, SHFM4, TP53CP, TP53L, 
TP73L, p40, p51, p53CP, p63, p73H, p73L 




Human TP63 was first isolated from human total 
genomic DNA by screening with an 800 bp PCR 
fragment obtained from probing with primers designed 
to anneal to regions in contiguous exons of p53 and 
p73, including the intervening introns (Yang et al., 
1998). The resulting clones recovered from SK-N-MC 
neuroepithelioma total genomic DNA encoded proteins 
with two different N termini (TA and ∆N) and five 
different C termini (α, β, γ, δ, and ε; figure 1) (Yang et 
al., 1998; Mangiulli et al., 2009). Short splicing 
isoforms lacking exon 4 have been observed in invasve 
breast carcinomas (de Biase et al., 2010) that are not 
presented in figure 1. 
Description 
The TP63 gene spans 267 kb, contains 16 exons, 
encodes 680 amino acids for the longest isoform, and 
has 12 isoforms formed by alternative promoter usage 
and alternative splicing (Augustin et al., 1998; Muzny 
et al., 2006; Parsons et al., 2009; Vanbokhoven et al., 
2011). The six variants with TA and ∆N at the N-
terminal and α, β, γ at the C-terminal are the most 
known and studied isoforms. 
Protein 
Description 
Human TP63 encodes the p63 protein, of which the 
longest isoform contains 680 amino acids, has 
molecular weights ranging from 44 to 77 kDa, 
depending on specific alternative promoter usage and 
alternative splicing (Augustin et al., 1998; Yang et al., 
1998). TP63 comprises up to five types of domains, 
depending on the isoform, and may contain 
transactivation (TA), DNA Binding (DBD), 
oligomerization (OD), C-terminal sterile alpha motif 
(SAM), and/or C-terminal transcription inhibitory (ID) 
domains (Moll and Slade, 2004). The N-terminus may 
consist of a TA domain or a truncated version (∆N) 
lacking the acidic TA domain that is derived from an 
alternative promoter and initiation codon in intron 3 
(Yang et al., 1998). The 3' end of both TAp63 and 
∆Np63 may be alternatively spliced to yield isoforms 
α, β, γ, and δ, while the ε-isoform is formed from 
transcriptional termination in exon 10 (Mangiulli et al., 
2009). TAp63α and ∆Np63α contain a protein-protein 
interaction SAM domain and a trans-inhibitory domain, 
resulting from the masking of N-terminal TA domain 
residues. The δ- and ε-isoform proteins are formed by 
transcriptional termination in the second TA domain 
and after the OD, respectively (Mangiulli et al., 2009) 
(figure 1). 
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Figure 1. The Human TP63 isoforms. A) Human TAp63 and ∆Np63 with α, β, γ, δ, ε splice variant protein isoforms are shown. 
TP63 protein functional domains are depicted. TA: transactivation domain; ∆N: N-terminally truncated isoform; DBD: DNA binding 
domain; OD: oligomerization domain; the second TA domain; SAM: sterile alpha motif; ID: inhibitory domain. B) Exon schema and 
corresponding domains of the human TP63 gene. Alternative promoter use produces TA (transactivation) and N-terminally truncated 




TP63 binds DNA as either a homo- or a heterotetrame, 
with isoform composition of the tetramer possibly 
determining transactivation activity. p63 may also form 
mixed dimers or tetramers with p73 at relatively higher 
affinity than with p53, suggesting functional cross talk 
to regulate transcriptional activity (Davison et al., 
1999; Natan and Joerger, 2012). p63 appears to form a 
dimer of dimers, with monomers consisting of a β-
strand followed by two helices (H1 and H2) that adopt 
a z-shaped double-hairpin conformation with little 
intramolecular contact between structural elements 
(Natan and Joerger, 2012). Monomers dimerize via 
intermolecular antiparallel β-sheet interactions and 
antiparallel packing of the H1 helices, with important 
hydrophobic contacts made by key leucine, valine, 
tyrosine, methionine, and isoleucine residues (Natan 
and Joerger, 2012). Tetramers are formed by 
hydrophobic H1-H1 interactions and H2-mediated 
contact where the H2 helices from the primary dimer 
clasps the adjacent dimer, packing the tetramer in an 
orthogonal fashion via H1 helices arrangement (Natan 
and Joerger, 2012). Analysis of the DBD of TP63  
shows higher similarity to that of p73 than p53, and 
appears to bind a 10-bp DNA sequence containing a 
"CATG" motif with A/T-rich flanking regions (Chen et 
al., 2011). 
Expression 
TP63 expression is found in fetal and adult tissues, 
including the skin, cervix, vaginal epithelium, 
urothelium, prostate, heart, testis, kidney, thymus, 
brain, and spleen (Yang et al., 1998). 
Immunohistochemistry of p63 often shows strong 
nuclear-localized staining in basal epithelial cells. 
Additionally, TA and ∆N isoforms appear to be 
differentially expressed in particular tissue types. 
TAp63 variants are prevalent in the heart, testis, 
kidney, thymus, brain, and cerebellum. ∆Np63 
transcripts are detected heavily in epithelial cells, 
kidney, spleen, and thymus, but not in the heart, liver, 
testis, or brain (Yang et al., 1998; Dötsch et al., 2010). 
Localisation 
As a transcription factor, p63 is normally present in the 
nucleus (Yang et al., 1998). 
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Function 
TP63 acts as a motif-specific transcriptional activator 
or repressor, depending on the presence of TA or ID 
domains in the specific p63 isoform (Yang et al., 1998). 
It plays a critical role in the maintenance of progenitor-
cell populations that encourage epithelial development 
and morphogenesis (Romano et al., 2009). ∆Np63, 
once thought to serve as a dominant negative regulator 
due to its lack of a full TA domain, has recently been 
implicated in transcriptionally activating and reprssing 
target genes such as Keratin 5 and Keratin 14 to dictate 
early epithelial development and determine 
keratinocyte cell fate and lineage choices (Yang et al., 
1998; Romano et al., 2009). Less is known about 
TAp63 function. Mice with germline deletion of 
TAp63 display blisters, decreased hair morphogenesis, 
and potential maintenance of adult stem cells, thoug  
full characterization of TAp63 function is lacking (Su 
et al., 2009). 
While the interactomes of TP53 and TP73 have been 
systematically analyzed and cataloged, until recently, 
no such information had been compiled for TP63 
(Tozluoglu et al., 2008; Collavin et al., 2010). Recent 
protein chip analysis has elucidated 144 proteins that
specifically interact with TP63 and are implicated in 
cell growth/death/survival, chromatin remodeling and 
gene regulation, RNA processing, protein trafficking 
and degradation, and other and epithelial differentiation 
(Huang et al., 2012). A representative protein and its 
function from each of the aforementioned categories 
are described below, while a complete list may be 
found in the supplemental data of Huang et al. (2012). 
Cell growth/survival: Signal Transducer and Activator 
of Transcription 3 (STAT3) - STAT3 is a latent 
cytoplasmic transcription factor activated in response to 
various interleukins and growth factors that binds the
promoter regions of IL-6-induced plasma protein and 
intermediate-early genes (Akira et al., 1994; 
McLoughlin et al., 2005; Huang et al., 2012). 
Chromatin remodeling: SWI/SNF Regulator of 
Chromatin 1 (SMARCC1) - SMARCC1 is a 
component of the larger SWI/SNF complex responsible 
for chromatin remodeling necessary for transcriptional 
activation of certain genes (Wang et al., 1996; Ring et 
al., 1998; Huang et al., 2012). 
Gene regulation/expression: Eukaryotic Translation 
Initiation Factor 4A2 (EIF4A2) - EIF4A2 plays an 
important role in the binding of mRNA to the 43S pre-
initiation complex during the beginning of protein 
synthesis (Sudo et al., 1995; Huang et al., 2012). 
RNA processing: Splicing Factor 3b, Subunit 4 
(SF3B4) - SF3B4 interacts with other spliceosome 
proteins to help cross-link a 29-nucleotide region in the 
pre-mRNA near the branch-point sequence in the A 
complex (Champion-Arnaud and Reed, 1994; Huang et 
al., 2012). 
Protein trafficking: Trafficking Protein Particle 
Complex 2-Like (TRAPPC2L) - TRAPPC2L is part of 
the TRAPP multi-subunit tethering complex involved 
in intracellular vesicle trafficking (Scrivens et al., 2011; 
Huang et al., 2012). 
Protein degradation: Ubiquitin Conjugation Factor E4 
B Isoform 1 (UFD2A) - UFD2A has been shown to 
promote monoubiquitination of p53 and, in 
combination with MDM2, to promote p53 
polyubiquitination (Wu and Leng, 2011; Wu et al., 
2011; Huang et al., 2012). 
Epithelial differentiation: Keratin 1 (KRT1) - KRT1 
is a marker for terminal differentiation in the 
mammalian epidermis (Lessin et al., 1988; Huang et 
al., 2012). 
Through protein-protein interactions with other 
transcription and cofactors, TP63 also contributes to the 
transcriptional regulation of genes involved in cellular 
differentiation, proliferation/survival, growth 
suppression, apoptosis, adhesion, inflammation, and
metabolism (Perez and Pietenpol, 2007; Viganò and 
Mantovani, 2007; Yang et al., 2011). Recent work by 
our laboratory has identified protein-protein 
interactions between ∆Np63α, TAp73, and c-REL that 
function to regulate key genes involved in growth arrest 
and apoptosis of mutant p53 head and neck squamous 
cell carcinoma (HNSCC) (Lu et al., 2011). Functionally 
important genes representing each of the 
aforementioned categories are described below, while 
more comprehensive reviews may be found in Perez 
and Pietenpol (2007) and Viganò and Mantovani 
(2007). 
Cellular differentiation: Jagged 1 (JAG1) - JAG1 is 
the ligand of the Notch receptor. It's binding causes a 
proteolytic cleavage cascade, leading to translocati n 
of the intracellular component of the Notch receptor 
and subsequent activation of transcription factors with 
key roles in cell differentiation and morphogenesis 
(Gray et al., 1999; Sasaki et al., 2002; Guarnaccia et al., 
2004). Overexpression of p63γ has been shown to 
dramatically upregulate JAG1 protein levels in 
colorectal cancer, osteogenic sarcoma, lung cancer, 
hepatocellular carcinoma, and glioma (Sasaki et al., 
2002). 
Proliferation/survival: Epidermal Growth Factor 
Receptor (EGFR) - EGFR is the receptor for epidermal 
growth factor and is involved in modulating cellular 
functions such as cell proliferation, differentiation, and 
survival by activating various intracellular signali g 
cascades such as RAS and STAT that transcribe target 
genes important in cellular proliferation and survival 
(Carpenter, 1984; Jamnongjit et al., 2005; Testoni et 
al., 2006). Knockdown of ∆Np63α has been shown to 
reduce expression of EGFR in keratinocytes (Testoni et 
al., 2006). 
Growth suppression: Cyclin-Dependent Kinase 
Inhibitor 1A (CDKN1A) - CDKN1A (p21) associates 
with cyclins A, D, and E to prevent the G1-S phase 
transition in mammals (el-Deiry et al., 1993; Westfall 
et al., 2003). Overexpression of ∆Np63α has been 
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shown to reduce expression of p21 in HEK cells 
(Westfall et al., 2003). 
Apoptosis: p53-Upregulated Modulator of Apoptosis 
(PUMA) - PUMA binds to BCL2 to induce rapid and 
profound apoptosis by cytochrome c release (Yu et al., 
2001; Flores et al., 2002). Additionally, recent work 
has shown that a complex of ∆Np63α, with TAp73 or 
c-REL, can modify expression of key growth arrest and
apoptotic genes such as p21WAF1, NOXA, and PUMA 
(Lu et al., 2011; Yang et al., 2011). 
Adhesion: Integrin Alpha 6 (ITGA6) - ITGA6 is a cell 
surface adhesion molecule that may help regulate 
migration and layer formation, especially in epithelial 
cells. Mouse models deficient in ITGA6 display sever  
blistering of the skin and other epithelia and die shortly 
after birth (Georges-Labouesse et al., 1996; Carroll et 
al., 2006). Loss of endogenous p63 in mammary 
epithelial cells has been shown to induce detachment 
and cell death, presumably because p63 regulates 
expression of key adhesion molecules such as ITGA6, 
ITGB1, ITGB4 other ECM components, and cadherins-
catenins (Carroll et al., 2006; Yang et al., 2011). 
Inflammation: ∆Np63 overexpression has been 
observed in head and neck squamous cell carcinoma 
(HNSCC), which are associated with inflammation. 
TNF-α, a potent pro-inflammatory cytokine, promoted 
NF-κB, c-REL and RELA complexes with nuclear 
∆Np63, to promote a broad-spectrum production of 
cytokines and chemokines (Lu et al., 2011; Yang et al., 
2011). In addition, in squamous epithelia of ∆Np63α 
transgenic mice, severe inflammation, skin lesions a d
erythema were observed after ∆Np63 expression was 
induced. Microscopically, hyperplastic and 
hyperproliferative epidermis with diffuse infiltration of 
inflammatory cells in the dermis was observed (Yang et 
al., 2011). NF-κB family proteins, c-Rel and RelA, and 
numerous inflammatory cytokines and chemokines 
were significantly upregulated in ∆Np63 transgenic 
mice. 
Metabolism: Fatty Acid Synthase (FASN) - FASN 
catalyzes the conversion of Acetyl-CoA and Malonyl-
CoA into long-chain saturated fatty acids with the help 
of NADPH (Wakil, 1989; D'Erchia et al., 2006). 
∆Np63α (and TAp73α) expression has also been shown 
to induce promoter and enhancer activity in human 
FASN gene by binding to p53 response elements 
(D'Erchia et al., 2006). 
Mouse models: TP63 knockout mice are born alive but 
have striking developmental defects including absent or 
truncated limbs, lack of stratified epithelia, and lack 
hair follicles, teeth, and mammary glands. Thus, TP63 
is essential for epidermal-mesenchymal interactions 
during embryonic development, including regenerative 
limb proliferation, craniofacial and epithelial 
development, and differentiation of squamous epithelia 
(Yang et al., 1998; Mills et al., 1999; McKeon, 2004; 
Laurikkala et al., 2006). Recently, ∆Np63α transgenic 
mice have been developed using tissue-specific 
tetracycline inducible expression. Mice expressing 
∆Np63α under a tissue-specific promoter (SPC) for 
lung epithelium exhibited Keratin 5 and 14 induction, 
trans-differentiation to an epidermal cell lineage, and 
squamous metaplasia. Overexpression of ∆Np63α 
under a K5 promoter in wild-type epidermis results in 
severe defects in hair follicle development and cycling, 
leading to severe hair loss and a depleted hair foll cle 
stem-cell niche (Romano et al., 2009; Romano et al., 
2010). In addition, ∆Np63α overexpression induced 
marked skin inflammation, and skin hyperplasia (Yang 
et al., 2011). A more detailed summary of the 
phenotypes of different p63 knockout and transgenic 
mouse models has recently been published 
(Vanbokhoven et al., 2011). 
Homology 
In addition to humans, the TP63 gene is conserved in 
chimpanzees, dogs, cows, mice, rats, chicken, and 
zebrafish, and evolutionary precursors have been 




Genome-wide association studies and in vivo work 
have identified TP63 mutations and/or overexpression 
in multiple cancers, including lung, bladder, 
esophageal, and head and neck squamous cell 
carcinoma (Rocco et al., 2006; Rothman et al., 2010; 
Hu et al., 2011; Stransky et al., 2011; Yang et al., 2011; 
Ellinghaus et al., 2012). While these studies have 
correlated certain mutations with an increased risk for 
cancer, the molecular effects of these mutations are not 
as well characterized as those in the aforementioned 
autosomal dominant disorders. Immunohistochemistry 
(IHC) in head and neck squamous cell carcinoma 
(HNSCC) has identified overexpression of TP63 
isoforms in the majority of tumor specimens. Although 
the tumorigenic effect of all the TP63 isoforms has yet 
to be fully understood, unregulated TP63 expression is 
an early pathogenic event in HNSCC and inhibition of 
TP63 can induce apoptotic cell death (Westfall and 
Pietenpol, 2004; Chen et al., 2005; Rocco et al., 2006). 
Additionally, ∆Np63α has been shown to increase the 
half-life of hypoxia-inducible factor 1α, leading to 
upregulation of vascular endothelial growth factor 
(VEGF) expression in vitro in human non-small cell 
carcinoma cell lines (Senoo et al., 2002). 
Transcriptional activation of matrix metalloproteass 
(MMPs) has also been seen with high levels of ∆Np63α 
(Patturajan et al., 2002; Hildesheim et al., 2004). 
TAp73/∆Np63α interaction has also been shown to 
mediate chemosensitivity to cisplatin in primary breast 
cancers (Leong et al., 2007). More recently, ∆Np63 
overexpression is shown in HNSCC to correlate with 
increased epithelial inflammation, proliferation, and 
migration by regulating gene programs important in 
cancer progression (Yang et al., 2011). In addition, 






Atlas Genet Cytogenet Oncol Haematol. 2013; 17(6)  418 
TNF-α, a potent pro-inflammatory cytokine, promoted 
c-REL translocation and complexes with nuclear 
∆Np63, while TAp73 dissociated from ∆Np63 and the 
promoters of key growth arrest and apoptosis genes 
p21CIP1/WAF1, NOXA, and PUMA. Increased 
nuclear ∆Np63α was detected in human HNSCC 
tumors, and hyperplastic squamous epithelia of 
transgenic mice overexpressing ∆Np63α (Lu et al., 
2011). Such a novel mechanism explains how 
inflammation activates proto-oncogenic NF-κB and 
overcomes TP53/p63/p73 family mediated tumor 
suppression. Furthermore, it has been found that 
∆Np63α interacts with IκB kinases, and IKKβ 
promotes ubiquitin-mediated proteasomal degradation 
of ∆Np63α. Conversely, IKKβ inhibition attenuated 
cytokine- or chemotherapy-induced degradation of 




ADULT syndrome may be caused by heterozygous 
mutations in the TP63 gene, including missense 
mutations R298Q and R227Q. Features include 
ectrodactyly, syndactyly, finger and toenail dysplaia, 
hypoplastic breasts and nipples, freckling, lacrimal duct 
atresia, frontal alopecia, primary hypodontia, and loss 
of permanent teeth (Reisler et al., 2006; Rinne et al., 
2006). 
Ectrodactyly, ectodermal dysplasia, and 
cleft lip/palate syndrome 3 (EEC3) 
Note 
EEC3 is an autosomal dominant disorder caused by a 
heterozygous mutation in TP63, most likely in the 
DNA-binding domain. Clinically, EEC3 presents with 
absence of the central parts of the hands and feet,
resulting in split-hand/foot malformations, ectodermal 
dysplasia, and cleft lip that may or may not include 
cleft palate (Maas et al., 1996; Akahoshi et al., 2003). 
Hay-Wells syndrome 
Note 
While similar to phenotype to ADULT syndrome and 
EEC3, Hay-Wells syndrome is caused by a 
heterozygous mutation in TP63 in the sterile alpha 
motif (SAM) domain. Hay-Wells Syndrome is 
characterized by congenital ectodermal dysplasia with
course, sparse hair, dystrophic nails, scalp infections, 
hypodontia, maxillary hypoplasia, and cleft lip/palate 
(Hay and Wells, 1976; McGrath et al., 2001). 
Limb-mammary syndrome (LMS) 
Note 
LMS is caused by a heterozygous mutation in the TP63 
gene and is allelic to ADULT syndrome. Features of 
LMS include severe hand/food anomalies and  
hypoplasia/aplasia of the mammary gland and nipples 
(Propping and Zerres, 1993; van Bokhoven et al., 
2001). 
To be noted 
Note 
Acknowledgements: supported by NIDCD Intramural 
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